Outcomes in COVID-19 AgNP studies

All studies   Mortality   Serious outcomes   Cases   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 82% 2 271 Improvement, Studies, Patients Relative Risk Mortality 56% 1 40 Cases 94% 1 231 RCTs 82% 2 271 Prophylaxis 94% 1 231 Late 56% 1 40 AgNP for COVID-19 c19early.org May 2025 FavorsAgNP Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wieler (RCT) 56% 0.44 [0.23-0.83] death 7/20 16/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Late treatment 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk Almanza-R.. (RCT) 94% 0.06 [0.02-0.25] cases 2/114 33/117 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00012 Prophylaxis 94% 0.06 [0.02-0.25] 2/114 33/117 94% lower risk All studies 82% 0.18 [0.03-1.23] 9/134 49/137 82% lower risk 2 AgNP COVID-19 studies c19early.org May 2025 Tau​2​ = 1.59, I​2​ = 83.8%, p = 0.08 Effect extraction pre-specified(most serious outcome) Favors AgNP Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wieler (RCT) 56% 0.44 [0.23-0.83] 7/20 16/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Late treatment 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk All studies 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk 1 AgNP COVID-19 mortality result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Favors AgNP Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wieler (RCT) 56% 0.44 [0.23-0.83] death 7/20 16/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Late treatment 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk All studies 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk 1 AgNP COVID-19 serious outcome c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Effect extraction pre-specified(most serious outcome) Favors AgNP Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Almanza-R.. (RCT) 94% 0.06 [0.02-0.25] cases 2/114 33/117 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00012 Prophylaxis 94% 0.06 [0.02-0.25] 2/114 33/117 94% lower risk All studies 94% 0.06 [0.02-0.25] 2/114 33/117 94% lower risk 1 AgNP COVID-19 case result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00012 Favors AgNP Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wieler (RCT) 56% 0.44 [0.23-0.83] death 7/20 16/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Late treatment 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk Almanza-R.. (RCT) 94% 0.06 [0.02-0.25] cases 2/114 33/117 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00012 Prophylaxis 94% 0.06 [0.02-0.25] 2/114 33/117 94% lower risk All studies 82% 0.18 [0.03-1.23] 9/134 49/137 82% lower risk 2 AgNP COVID-19 Randomized Controlled Trials c19early.org May 2025 Tau​2​ = 1.59, I​2​ = 83.8%, p = 0.08 Effect extraction pre-specified(most serious outcome) Favors AgNP Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wieler (RCT) 56% 0.44 [0.23-0.83] 7/20 16/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Late treatment 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk All studies 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk 1 AgNP COVID-19 RCT mortality result c19early.org May 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Favors AgNP Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wieler (RCT) 56% 0.44 [0.23-0.83] death 7/20 16/20 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.011 Late treatment 56% 0.44 [0.23-0.83] 7/20 16/20 56% lower risk Almanza-R.. (RCT) 94% 0.06 [0.02-0.25] cases 2/114 33/117 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.00012 Prophylaxis 94% 0.06 [0.02-0.25] 2/114 33/117 94% lower risk All studies 82% 0.18 [0.03-1.23] 9/134 49/137 82% lower risk 2 AgNP COVID-19 peer reviewed studies c19early.org May 2025 Tau​2​ = 1.59, I​2​ = 83.8%, p = 0.08 Effect extraction pre-specified(most serious outcome) Favors AgNP Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wieler (RCT) 56% 0.44 [0.23-0.83] death 7/20 16/20 Improvement, RR [CI] Treatment Control Almanza-R.. (RCT) 94% 0.06 [0.02-0.25] cases 2/114 33/117 Almanza-R.. (RCT) 49% 0.51 [0.33-0.81] misc. 21/114 42/117 AgNP COVID-19 outcomes c19early.org May 2025 Favors AgNP Favors control